Skip to content

Azilsartan

    DEA Class; Rx

    Common Brand Names; Edarbi

    • ARBs

    Angiotensin II receptor antagonist
    Used for hypertension
    Black box warning for use during pregnancy

    Indicated for hypertension, either alone or in combination with other antihypertensives

    For the treatment of hypertension, either alone or in combination with other antihypertensive agents.

    Hypersensitivity

    Do not coadminister with aliskiren in patients with diabetes

    • Diarrhea (2%)
    • Nausea
    • Asthenia
    • Fatigue
    • Muscle spasm
    • Dizziness
    • Postural hypotension
    • Cough
    • Nausea
    • Muscle spasm
    • Rash, pruritus, angioedema

    Abnormally high serum creatinine values more likely reported in patients aged 75 or older

    Caution with hyperkalemia

    NSAIDs may attenuate antihypertensive response

    Coadministration with NSAIDs increase risk of renal impairment including acute renal failure

    Pregnancy Category: C (1st trimester); D (2nd and 3rd trimesters)

    Discontinue as soon as possible when pregnancy is detected; affects renin-angiotensin system causing oligohydramnios, which may result in fetal injury and/or death

    Lactation: unknown whether distributed in breast milk, decide on alternate antihypertensive therapy or do not breastfeed

    Adults

    80 mg/day PO.

    Geriatric

    80 mg/day PO.

    Adolescents

    Safety and efficacy have not been established.

    Children

    Safety and efficacy have not been established.

    Infants

    Safety and efficacy have not been established.

    Neonates

    Safety and efficacy have not been established.

    Azilsartan

    tablet

    • 40mg
    • 80mg